Literature DB >> 13596878

Clinical problems in the antibiotic treatment of gonorrhoea.

R R WILLCOX.   

Abstract

After briefly reviewing the history of penicillin therapy in gonorrhoea, the author shows that the number of cures effected with the repository penicillins, although originally very high, has diminished considerably in recent years, despite a general tendency to increase the dosage. The reduced efficacy of PAM and benzathine penicillin is demonstrated by an exposition of the current results obtained with these two preparations in the treatment of gonorrhoea patients in London. Some of the difficulties involved in distinguishing between treatment failures and reinfections are discussed.The paper continues with an examination of the possible alternatives to repository penicillin in the treatment of gonorrhoea. Data are given on the comparative efficacy of a number of prepations, including mixed penicillins, phenoxymethyl penicillin and various other antibiotics, such as streptomycin and the tetracycline group.The problem of re-examination of treated gonorrhoea cases is also dealt with, practical reasons being given for restricting the period of follow-up to three weeks.Finally, in a discussion of possible future developments, the author suggests a number of measures designed to prevent a further loss of sensitivity to penicillin in the gonococcus.

Entities:  

Keywords:  ANTIBIOTICS/therapeutic use; GONORRHEA/therapy; PENICILLIN/therapeutic use

Mesh:

Substances:

Year:  1958        PMID: 13596878      PMCID: PMC2537708     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  32 in total

1.  Norway conquers venereal diseases.

Authors:  T D ELIOT
Journal:  Br J Vener Dis       Date:  1955-03

2.  [Additional experiments on the penicillin treatment of acute gonorrhea].

Authors:  A LODIN
Journal:  Sven Lakartidn       Date:  1956-01-05

3.  Problems of venereal disease control in Poland.

Authors:  J TOWPIK
Journal:  Br J Vener Dis       Date:  1957-06

4.  Clinical evaluation of a new triple penicillin salt in the treatment of acute gonorrhoea.

Authors:  A J NELSON; G W SLEATH
Journal:  Can J Public Health       Date:  1956-09

5.  Survey of the venereal disease situation in France.

Authors:  P DUREL
Journal:  Br J Vener Dis       Date:  1956-09

6.  Need for repeated microscopical tests in gonorrhoea.

Authors:  P A CLEMENTS
Journal:  Br Med J       Date:  1955-12-24

7.  The male gonorrhoea carrier; report of seven cases.

Authors:  J B BITTINER; G O HORNE
Journal:  Br J Vener Dis       Date:  1955-09

8.  Gonorrhoea in N. Africa and Central Mediterranean.

Authors:  D J Campbell
Journal:  Br Med J       Date:  1944-07-08

9.  The evolution of syphilis after small doses of penicillin; a critical survey.

Authors:  E CRONIN
Journal:  Br J Vener Dis       Date:  1947-03

10.  Gonorrhoea and penicillin; is a 6 months' surveillance period necessary?

Authors:  W V MACFARLANE
Journal:  Br J Vener Dis       Date:  1950-06
View more
  6 in total

1.  THE NEWER PENICILLINS IN THE TREATMENT OF GONORRHOEA.

Authors:  R R WILLCOX
Journal:  Postgrad Med J       Date:  1964-12       Impact factor: 2.401

2.  Treatment problems of gonorrhoea.

Authors:  R R WILLCOX
Journal:  Bull World Health Organ       Date:  1961       Impact factor: 9.408

3.  Sensitivity to penicillin of Neisseria gonorrhoeae. Relationship to the results of treatment.

Authors:  D A Leigh; J Le Franc; A R Turnbull
Journal:  Br J Vener Dis       Date:  1969-06

4.  Treatment of gonococcal urethritis with single injections of 2-4 mega units of aqueous procaine penicillin.

Authors:  G D Morrison; R J Cobbold; S Bor; R J Spitzer; D N Foster; R R Willcox
Journal:  Br J Vener Dis       Date:  1968-12

5.  Guide to adequate treatment of gonorrhoea complicated by Staphylococcus albus.

Authors:  R L Tawes
Journal:  Br J Vener Dis       Date:  1966-09

6.  Epidemiological aspects of gonococcal infections.

Authors:  R R WILLCOX
Journal:  Bull World Health Organ       Date:  1961       Impact factor: 9.408

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.